Oncology Division
Alphabetical list (active faculty):   
Nusayba A. Bagegni

Nusayba A. Bagegni, MD

Assistant Professor

Department of Medicine

Oncology Division

Medical Oncology

Clinical Interests

  • Breast cancer

Research Interests

  • Breast cancer clinical trials
  • Developmental therapeutics
  • HER2 positive breast cancer
  • Metastatic breast cancer


  • 314-362-5654 (office)
  • 314-362-7086 (fax)
  • Division of Oncology
    Mail Stop 8056-0029-11
    Washington University
    660 South Euclid Avenue
    St. Louis, MO 63110
  • 11th Floor, Mid Campus Center (office)

Original Articles

  • Genetic Alterations Detected by Circulating Tumor DNA in HER2-Low Metastatic Breast Cancer
    Hensing WL, Gerratana L, Clifton K, Medford AJ, Velimirovic M, Shah AN, D'Amico P, Reduzzi C, Zhang Q, Dai CS, Denault EN, Bagegni NA, Opyrchal M, Ademuyiwa FO, Bose R, Behdad A, Ma CX, Bardia A, Cristofanilli M, Davis AA
    Clin Cancer Res 2023 Jun 2:CCR-22-3785; [ahead of print]
  • A Phase II Study of Palbociclib Plus Letrozole Plus Trastuzumab as Neoadjuvant Treatment for Clinical Stages II and III ER+ HER2+ Breast Cancer (PALTAN)
    Ademuyiwa FO, Northfelt DW, O'Connor T, Levine E, Luo J, Tao Y, Hoog J, Laury ML, Summa T, Hammerschmidt T, Guo Z, Frith A, Weilbaecher K, Opyrchal M, Aft R, Clifton K, Suresh R, Bagegni N, Hagemann IS, Iglesia MD, Ma CX
    NPJ Breast Cancer 2023 Jan 6;9(1):1
  • Circulating Tumour DNA Characterisation of Invasive Lobular Carcinoma in Patients With Metastatic Breast Cancer
    Davis AA, Gerratana L, Clifton K, Medford AJ, Velimirovic M, Hensing WL, Bucheit L, Shah AN, D'Amico P, Reduzzi C, Zhang Q, Dai CS, Denault EN, Bagegni NA, Opyrchal M, Ademuyiwa FO, Bose R, Gradishar WJ, Behdad A, Ma CX, Bardia A, Cristofanilli M
    EBioMedicine 2022 Dec;86:104316
  • Management of Diarrhea in Patients With HER2-Positive Breast Cancer Treated With Neratinib: A Case Series and Summary of the Literature
    Kruse ML, Kang IM, Bagegni NA, Howell WT, Moore HCF, Bedell CH, Stokoe CT
    Oncol Ther 2022 Jun;10(1):279-289
  • Targeted Treatment for High-Risk Early-Stage Triple-Negative Breast Cancer: Spotlight on Pembrolizumab
    Bagegni NA, Davis AA, Clifton KK, Ademuyiwa FO
    Breast Cancer (Dove Med Press) 2022 Apr 29;14:113-123
  • Phase 1b Trial of Anti-VEGF/PDGFR Vorolanib Combined With Immune Checkpoint Inhibitors in Patients With Advanced Solid Tumors
    Bagegni NA, Park H, Kraft K, O-Toole M, Gao F, Waqar SN, Ratner L, Morgensztern D, Devarakonda S, Amin M, Baggstrom MQ, Liang C, Selvaggi G, Wang-Gillam A
    Cancer Chemother Pharmacol 2022 Apr;89(4):487-497
  • Immunogenomic Profiling and Pathological Response Results From a Clinical Trial of Docetaxel and Carboplatin in Triple-Negative Breast Cancer
    Ademuyiwa FO, Chen I, Luo J, Rimawi MF, Hagemann IS, Fisk B, Jeffers G, Skidmore ZL, Basu A, Richters M, Ma CX, Weilbaecher K, Davis J, Suresh R, Peterson LL, Bose R, Bagegni N, Rigden CE, Frith A, Rearden TP, Hernandez-Aya LF, Roshal A, Clifton K, Opyrchal M, Akintola-Ogunremi O, Lee BH, Ferrando-Martinez S, Church SE, Anurag M, Ellis MJ, Gao F, Gillanders W, Griffith OL, Griffith M
    Breast Cancer Res Treat 2021 Aug;189(1):187-202
  • Mutation Profile Differences in Younger and Older Patients With Advanced Breast Cancer Using Circulating Tumor DNA (CtDNA)
    Clifton K, Luo J, Tao Y, Saam J, Rich T, Roshal A, Frith A, Rigden C, Ademuyiwa F, Weilbaecher K, Hernandez-Aya L, Peterson LL, Bagegni N, Suresh R, Bose R, Opyrchal M, Wildes TM, Ma C
    Breast Cancer Res Treat 2021 Feb;185(3):639-646
  • Radiation-Induced Brachial Plexopathy in Patients With Breast Cancer Treated With Comprehensive Adjuvant Radiation Therapy
    Rudra S, Roy A, Brenneman R, Gabani P, Roach MC, Ochoa L, Prather H, Appleton C, Margenthaler J, Peterson LL, Bagegni NA, Zoberi JE, Garcia-Ramirez J, Thomas MA, Zoberi I
    Adv Radiat Oncol 2020 Oct 27;6(1):100602
  • Age-Related Disparities in Older Women With Breast Cancer
    Bagegni NA, Peterson LL
    Adv Cancer Res 2020;146:23-56
  • Clinical Outcomes With Neoadjuvant Versus Adjuvant Chemotherapy for Triple Negative Breast Cancer: A Report From the National Cancer Database
    Bagegni NA, Tao Y, Ademuyiwa FO
    PLoS One 2019 Sep 19;14(9):e0222358
  • Cellular Stressors Contribute to the Expansion of Hematopoietic Clones of Varying Leukemic Potential
    Wong TN, Miller CA, Jotte MRM, Bagegni N, Baty JD, Schmidt AP, Cashen AF, Duncavage EJ, Helton NM, Fiala M, Fulton RS, Heath SE, Janke M, Luber K, Westervelt P, Vij R, DiPersio JF, Welch JS, Graubert TA, Walter MJ, Ley TJ, Link DC
    Nat Commun 2018 Jan 31;9(1):455
  • Serum Thymidine Kinase 1 Activity as a Pharmacodynamic Marker of Cyclin-Dependent Kinase 4/6 Inhibition in Patients With Early-Stage Breast Cancer Receiving Neoadjuvant Palbociclib
    Bagegni N, Thomas S, Liu N, Luo J, Hoog J, Northfelt DW, Goetz MP, Forero A, Bergqvist M, Karen J, Neumuller M, Suh EM, Guo Z, Vij K, Sanati S, Ellis M, Ma CX
    Breast Cancer Res 2017 Nov 21;19(1):123
  • Pain Management
    Bagegni N, Sheldahl A, Dans MC
    In: The Washington Manual of Outpatient Internal Medicine, 2nd Edition (DeFer TM, Sateia H, eds), Philadelphia: Wolters Kluwer, 2015
  • Risk of Early & Late Obstetric Complications in Women with IVF-Conceived Pregnancies and Polycystic Ovary Syndrome (PCOS)
    Bagegni NA, Blaine J, VanVoorhis B, Dokras A
    Proceedings in Obstetrics and Gynecology 2010 Oct;1(2):2
  • Solution Structure of Inhibitor-Free Human Metalloelastase (MMP-12) Indicates an Internal Conformational Adjustment
    Bhaskaran R, Palmier MO, Bagegni NA, Liang X, Van Doren SR
    J Mol Biol 2007 Dec 14;374(5):1333-44